Dosing Strategies of Botulinum Toxin for Primary Axillary Hyperhidrosis: A Meta-Analytic Review
Dr Ahmed Haq · Published 17 December 2024 · Updated 18 August 2026 · Aesthetic Intelligence (ISSN 2979-8116)
Abstract
Background. Botulinum toxin type A is an established treatment for primary axillary hyperhidrosis, acting by inhibiting acetylcholine release at eccrine sweat glands. Because effects are temporary and treatment costly, determining the optimal dose per axilla that balances efficacy, duration, cost and safety, without unnecessarily raising antibody-formation risk, is an important clinical question.
Methods. A meta-analytic literature review identified randomised controlled trials comparing different botulinum toxin dosing regimens (onabotulinumtoxinA, abobotulinumtoxinA, and cross-formulation comparisons) for primary axillary hyperhidrosis, extracting dose, sweat-reduction outcomes, duration of effect and adverse event data; findings were synthesised qualitatively due to outcome heterogeneity.
Results. Across trials, doses of 25-75 U onabotulinumtoxinA and 100-200 U abobotulinumtoxinA per axilla produced equivalent efficacy, with no significant dose-response benefit above roughly 50 U Botox or 100 U Dysport. Duration of anhidrotic effect was consistently 4-9 months regardless of dose, and higher doses conferred no meaningful extension. Adverse events were minimal across all dose groups with no increase at higher doses.
Conclusion. For primary axillary hyperhidrosis, lower-to-moderate botulinum toxin doses achieve near-maximal efficacy and duration comparable to higher doses, indicating a therapeutic plateau. Standard, cost-effective dosing protocols are supported over dose escalation, which offers no added clinical benefit while carrying theoretical immunogenicity risk.
The finding, in one line
Across every randomised comparison published to date, more toxin does not mean more anhidrosis or more months. Efficacy for primary axillary hyperhidrosis plateaus at roughly 50 U onabotulinumtoxinA (or 100 U abobotulinumtoxinA) per axilla. Above that, the patient pays more, carries a marginally higher theoretical immunogenic load, and sweats exactly as little as they would have on the standard dose.
Introduction
Primary axillary hyperhidrosis is excessive, focal, non-thermoregulatory underarm sweating that materially damages work, clothing and social confidence. Intradermal botulinum toxin type A is an established second-line therapy after topical aluminium chloride and glycopyrronium, acting by blocking acetylcholine release at the cholinergic sympathetic fibres supplying eccrine sweat glands.
The clinical question is not whether it works — it plainly does — but how much to use. Early uncontrolled reports implied that larger doses bought longer sweat-free intervals, and whole-vial dosing became habit in several markets. This review synthesises the randomised evidence that directly compared dosing regimens, and converts it into a working protocol.
Methods
Randomised controlled trials of any year comparing at least two botulinum toxin type A dosing regimens for primary axillary hyperhidrosis were identified, across onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA. Extracted variables were dose per axilla, gravimetric sweat reduction, Hyperhidrosis Disease Severity Scale (HDSS) response, duration of effect and adverse events. Because outcome metrics were heterogeneous, findings were synthesised qualitatively rather than pooled statistically.
Table 1. Randomised dose-comparison trials
| Study | Toxin | Doses compared | Design | Efficacy | Duration |
|---|---|---|---|---|---|
| Lowe et al. (2007) | OnabotulinumtoxinA (Botox) | 50 U vs 75 U per axilla (placebo-controlled) | N = 322 · double-blind RCT · 52 weeks | ~75% achieved ≥2-point HDSS improvement at 4 weeks on both doses (25% placebo). No efficacy difference between doses. | Median 6.5–6.7 months (both doses) |
| Heckmann et al. (2005) | AbobotulinumtoxinA (Dysport) | 100 U vs 200 U per axilla (intra-patient, side-by-side) | N = 43 · randomised · 96 weeks with re-treatment | Sweat production fell to ~10–20% of baseline by 2 weeks on both sides. No difference at any time point. | ~6–9 months (both doses) |
| Talarico-Filho et al. (2007) | Onabotulinum vs Abobotulinum | 50 U Botox vs 150 U Dysport per axilla (1:3 ratio) | N = 10 · double-blind · 12 months | All axillae achieved ≥50% sweat reduction at 1 month; mean reduction ~98% vs ~99%. Formulations equivalent at 1:3. | ~260 days vs ~290 days |
| Siri-Archawawat & Tawanwongsri (2023) | OnabotulinumtoxinA (Botox) | 25 U vs 50 U per axilla (intra-patient, side-by-side) | N = 12 · single-blind RCT · 12 weeks | No difference in gravimetric sweat rate, starch-iodine area, HDSS or quality of life between 25 U and 50 U. | Maintained through 3 months (both doses) |
HDSS: Hyperhidrosis Disease Severity Scale. Intra-patient designs inject one dose per axilla, controlling for patient-level variation in sweat rate.
Results
OnabotulinumtoxinA
Doses between 25 U and 75 U per axilla produce comparable outcomes. Lowe's 322-patient trial found identical HDSS response and median durations of 197 days (75 U) versus 205 days (50 U) — a difference of eight days in favour of the lower dose, which is to say noise. The 2023 side-by-side trial pushed the floor lower still, finding 25 U indistinguishable from 50 U over three months of follow-up in a small cohort.
AbobotulinumtoxinA
100 U per axilla is sufficient for maximal benefit; 200 U added nothing across 48 weeks of observation in Heckmann's intra-patient comparison. Given that early practice frequently used a 500 U vial split between two axillae, this represents a substantial and evidence-supported reduction in drug cost per treatment.
Cross-formulation equivalence
Dosed at 1:3 (50 U onabotulinumtoxinA versus 150 U abobotulinumtoxinA), the two formulations performed equivalently with mean sweat reductions of ~98% and ~99% respectively. IncobotulinumtoxinA is used unit-for-unit with onabotulinumtoxinA in practice; its complexing-protein-free formulation is theoretically attractive for the repeated dosing hyperhidrosis requires, though comparative hyperhidrosis trials remain small. For the practical arithmetic of switching brands, see our brand conversion and dilution guide.
Duration and re-treatment
Duration clusters at 4–9 months with a median of 6–7, and does not lengthen meaningfully with dose. This matters commercially as well as clinically: patients told to expect "three-monthly Botox" for sweating are usually being treated to a diary rather than to a symptom. Re-treatment is appropriate when HDSS returns to 3–4 or when gravimetric sweat again exceeds baseline thresholds.
Safety
- Injection pain — the dominant complaint; mitigated by topical anaesthesia, ice, small-gauge needles and a slow intradermal technique.
- Local reactions — transient erythema, oedema and bruising at puncture sites.
- Compensatory sweating — reported by a minority, generally mild and non-limiting.
- Muscle weakness — not clinically observed at intradermal axillary doses; the plane is dermal, not muscular.
Adverse events did not increase with dose in any trial — so the argument against escalation is economic and immunological rather than one of acute safety. Secondary hyperhidrosis (endocrine, neurological, malignant or drug-induced) must be excluded before treating; sudden-onset, nocturnal, generalised or asymmetrical sweating is referred, not injected.
HSI practice points
Start at 50 U per axilla
OnabotulinumtoxinA 50 U (or incobotulinumtoxinA 50 U) per axilla sits on the efficacy plateau. 75 U buys no additional anhidrosis and no additional months.
100 U Dysport, not 250 U
AbobotulinumtoxinA 100 U per axilla matches 200 U in every controlled comparison. Whole-vial dosing is a habit inherited from early open-label practice, not an evidence-based protocol.
Map before you inject
Minor starch-iodine test defines the hyperhidrotic field. Poor outcomes are far more often a mapping failure — treating a 100 cm² field with a 50 cm² injection grid — than a dosing failure.
Grid, depth and volume
10–15 intradermal points per axilla, 1–2 cm apart, 2–3 mm deep at a shallow angle so the bleb stays dermal. Deeper deposition wastes toxin in subcutaneous fat and blunts the result.
Re-treat on symptoms, not the calendar
Median duration is 6–7 months. Fixed 3-monthly intervals add cost and theoretical immunogenicity without benefit; re-treat when HDSS returns to 3–4.
Dose escalation is not the answer to early failure
If a patient relapses at 8 weeks, review reconstitution, storage, injection depth and field mapping before increasing units. True primary non-response is rare.
Cost implications
Halving the dose per axilla halves the drug component of the treatment without measurably shortening the sweat-free interval. For a clinic treating hyperhidrosis regularly, that difference funds either a lower patient price or a higher margin — and it removes the awkward conversation that follows when a patient discovers a colleague achieved the same result for half the toxin. Evidence-based dosing is, in this instance, also the commercially superior position.
Conclusion
For primary axillary hyperhidrosis, the dose–response curve flattens early. Standard dosing — approximately 50 U onabotulinumtoxinA or 100 U abobotulinumtoxinA per axilla, delivered intradermally across an accurately mapped field — achieves near-maximal anhidrosis with a 6–7 month median duration and a benign side-effect profile. Escalation beyond that plateau adds cost and theoretical immunogenicity without adding clinical benefit. Where results disappoint, the correction lies in mapping, depth and technique rather than in units.
References
- Lowe NJ, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicentre double-blind, randomised, placebo-controlled study. PubMed
- Heckmann M, et al. Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomised, side-by-side, open-label study. JAMA Dermatology
- Nawrocki S, Cha J. Current and emerging medical therapies for primary hyperhidrosis. PMC / NCBI
- Efficacy and safety of botulinum toxin in focal hyperhidrosis. Toxins (MDPI)
- International Hyperhidrosis Society — clinical resources. sweathelp.org
Continue learning
Declarations
- Peer review:
- This article underwent single-blind external peer review by at least two independent reviewers, followed by editorial acceptance.
- Conflicts of interest:
- The author(s) declare no competing financial or commercial interests relating to the content of this article. Editorial decisions are made independently of the Harley Street Institute's commercial training activities.
- Funding:
- No external funding was received for the preparation of this article.
- Licence:
- © 2024 Harley Street Institute. Open access article distributed under the Creative Commons Attribution 4.0 International Licence (CC BY 4.0), permitting unrestricted use with appropriate citation.